Cetuximab-associated pulmonary toxicity in concurrent chemoradiation for the treatment of a squamous cell carcinoma of the head and neck.
John D MayfieldCatherine E MercadoFrederic J KayeWilliam M MendenhallPublished in: Head & neck (2019)
Although severe pulmonary toxicity caused by EGFR inhibitors has been well described in the literature, ILD caused by cetuximab, an EGFR monoclonal antibody, is rare and not well-documented. Given its life-threatening effects, awareness of this potential side effect and early diagnosis is critical.
Keyphrases
- locally advanced
- monoclonal antibody
- squamous cell carcinoma
- small cell lung cancer
- rectal cancer
- pulmonary hypertension
- epidermal growth factor receptor
- tyrosine kinase
- radiation therapy
- oxidative stress
- systematic review
- metastatic colorectal cancer
- interstitial lung disease
- early onset
- systemic sclerosis
- combination therapy
- drug induced
- smoking cessation